Strides Pharma receives USFDA EIR for Bengaluru facility
USFDA classifies inspection outcome as Voluntary Action Indicated following May 2026 cGMP inspection
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Voluntary Action Indicated
USFDA classifies Aurobindo Pharma’s Raleigh plant as VAI
The facility received 11 observations during the USFDA inspection conducted from March 24 to April 10, 2025
Cipla’s manufacturing facility in Goa gets VAI classification
The US FDA conducted a cGMP inspection between June 10-21, 2024
Biocon Biologics’ Bengaluru unit gets VAI classification by US FDA
This relates to the cGMP inspection conducted by the agency between February 20-28, 2024
Strides Alathur receives EIR from USFDA for its Chennai facility
The facility manufactures tablets and capsules and supports several current and future products for the US markets
US FDA completes inspection at Alkem’s Baddi facility
The Inspection was classified as Voluntary Action Indicated (VAI)
Alembic Pharma gets VAI classification from USFDA for Panelav facility
The US FDA inspection was conducted from March 9-13, 2020